BeVigilant™ OraFusion™ System**
Granted FDA Breakthrough Device Designation
The BeVigilant™ OraFusion™ System** is Not Available For Sale in the U.S.
The BeVigilant™ OraFusion™ System** identifies the presence of biomarkers associated with oral cancer in 15 minutes or less.
![VIG_81 BeVigilant™ OraFusion™ System with Cassette Open](https://vigilantbiosciences.com/wp-content/uploads/VIG_81.png)
BeVigilant™ OraFusion™ System**
With the BeVigilant™ OraFusion™ System, clinicians can get a simple and accurate* assessment to aid in the early detection of oral cancer. The platform provides a qualitative result at the point–of–care, reporting low, moderate or elevated levels of risk associated with oral cancer. Learn how it benefits dentists and their patients:
BeVigilant™ OraFusion™ Test
![New Workflow Updated Moderate Risk App Chart](https://vigilantbiosciences.com/wp-content/uploads/New-Workflow-Updated.png)
How the BeVigilant™ OraFusion™ System** Works
BeVigilant™ OraFusion™ System is an easy-to-use, accurate*, qualitative tool for frontline healthcare clinicians assessing potentially at-risk patients for oral cancer.
Created to improve outcomes through earlier intervention, the BeVigilant™ OraFusion™ System** is
![Check Mark Icon](https://vigilantbiosciences.com/wp-content/uploads/2-2.png)
ACCURATE*
Using multiple biomarkers in conjunction with clinical risk factors provides an accurate risk assessment
![Check Mark Icon](https://vigilantbiosciences.com/wp-content/uploads/2-2.png)
NON-INVASIVE
Simple saliva test
![Check Mark Icon](https://vigilantbiosciences.com/wp-content/uploads/2-2.png)
Fast
Results in just 15 minutes or less
The BeVigilant™ OraFusion™ System is patent pending and available in select markets outside the United States. Interested in learning more about the technology’s availability in your market?
Schedule a demo to discover if the BeVigilant OraFusion System is right for your practice.
*Clinical Data on File